Objective: To evaluate the clinical effect of Lilalutide in the treatment of type 2 diabetes mellitus with atherosclerosis and its effects on blood glucose, blood lipid, blood pressure and carotid plaque. Methods: 82 ...Objective: To evaluate the clinical effect of Lilalutide in the treatment of type 2 diabetes mellitus with atherosclerosis and its effects on blood glucose, blood lipid, blood pressure and carotid plaque. Methods: 82 patients with type 2 diabetes complicated with atherosclerosis who were treated in our hospital from March 2017 to August 2018 were selected. The patients were randomly divided into control group and observation group with 41 cases in each group. All patients were given diet and exercise intervention and oral statins. On this basis, the control group was treated with metformin, the observation group was treated with Liraglutide, and the two groups were treated continuously for 6 months. The fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), systolic blood pressure (SBP), diastolic blood pressure (DBP), Body mass index (BMI), body mass, waist circumference, and carotid plaque (soft plaque, flat plaque, hard plaque, mixed plaque) were observed before and after treatment. The curative effect and the incidence of major adverse reactions between the two groups were compared. Results: The total effective rate of the observation group was higher than that of the control group. After treatment, the 2hPG, HbA1c and FPG in the observation group were lower than those in the control group;the TG, TC and LDL-C were lower than those in the control group, while HDL-C was higher than that in the control group;the SBP and DBP were lower than those in the control group. the body mass, waist circumference and BMI were lower than those of control group;the IMT was lower than that in the control group;plaque detection rate was lower than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Liraglutide is effective in treating type 2 diabetes mellitus with atherosclerosis. It has obvious advantages in improving blood sugar, blood lipid, blood pressure and weight control, and does not increase adverse drug reactions. It is worthy of clinical application.展开更多
基金National Natural Science Foundation of China(81870544).
文摘Objective: To evaluate the clinical effect of Lilalutide in the treatment of type 2 diabetes mellitus with atherosclerosis and its effects on blood glucose, blood lipid, blood pressure and carotid plaque. Methods: 82 patients with type 2 diabetes complicated with atherosclerosis who were treated in our hospital from March 2017 to August 2018 were selected. The patients were randomly divided into control group and observation group with 41 cases in each group. All patients were given diet and exercise intervention and oral statins. On this basis, the control group was treated with metformin, the observation group was treated with Liraglutide, and the two groups were treated continuously for 6 months. The fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), systolic blood pressure (SBP), diastolic blood pressure (DBP), Body mass index (BMI), body mass, waist circumference, and carotid plaque (soft plaque, flat plaque, hard plaque, mixed plaque) were observed before and after treatment. The curative effect and the incidence of major adverse reactions between the two groups were compared. Results: The total effective rate of the observation group was higher than that of the control group. After treatment, the 2hPG, HbA1c and FPG in the observation group were lower than those in the control group;the TG, TC and LDL-C were lower than those in the control group, while HDL-C was higher than that in the control group;the SBP and DBP were lower than those in the control group. the body mass, waist circumference and BMI were lower than those of control group;the IMT was lower than that in the control group;plaque detection rate was lower than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Liraglutide is effective in treating type 2 diabetes mellitus with atherosclerosis. It has obvious advantages in improving blood sugar, blood lipid, blood pressure and weight control, and does not increase adverse drug reactions. It is worthy of clinical application.
